0.46

9.79% 0.041

Nextcure Inc (NXTC)

Overview News Price History Option Chain Financials Why NXTC Down? Discussions Forecast

Nextcure Inc stock is traded at $0.46, with a volume of 321.69K. It is up +9.79% in the last 24 hours and down -19.16% over the past month. NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Previous Close:

$0.419

Open:

$0.4301

24h Volume:

321.69K

Relative Volume:

2.42

Market Cap:

$10.33M

Revenue:

Net Income/Loss:

$-58.52M

P/E Ratio:

-0.2201

EPS:

-2.09

Net Cash Flow:

$-45.03M

1W Performance:

+27.35%

1M Performance:

-19.16%

6M Performance:

-66.91%

1Y Performance:

-64.34%

1-Day Range:

$0.395

$0.499

1-Week Range:

$0.3499

$0.499

52-Week Range:

$0.224

$1.8199

Nextcure Inc Stock (NXTC) Company Profile

Name

Nextcure Inc

Sector

Healthcare (1154)

Industry

Biotechnology (677)

Phone

240-399-4900

Address

9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD

Employee

Twitter

@nextcureinc

Next Earnings Date

2025-03-07

Latest SEC Filings

NXTC's Discussions on Twitter

Compare NXTC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NXTC Nextcure Inc	0.46	10.33M	0	-58.52M	-45.03M	-2.09
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-04-22	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-22	Initiated	Ladenburg Thalmann	Buy
Mar-05-21	Upgrade	Truist	Hold → Buy
Jan-15-21	Downgrade	BofA Securities	Neutral → Underperform
Jul-16-20	Upgrade	The Benchmark Company	Hold → Buy
Jul-13-20	Downgrade	ROTH Capital	Buy → Neutral
Jul-13-20	Downgrade	SunTrust	Buy → Hold
Jun-01-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-01-20	Downgrade	The Benchmark Company	Buy → Hold
May-26-20	Initiated	JMP Securities	Mkt Outperform
Mar-24-20	Initiated	The Benchmark Company	Buy
Mar-02-20	Initiated	ROTH Capital	Buy
Jan-13-20	Initiated	SunTrust	Buy
Dec-05-19	Initiated	Needham	Buy
Nov-26-19	Initiated	BTIG Research	Buy
Jul-09-19	Initiated	BofA/Merrill	Buy
Jun-03-19	Initiated	Morgan Stanley	Overweight
Jun-03-19	Initiated	Piper Jaffray	Overweight

View All

Nextcure Inc Stock (NXTC) Latest News

08:02 AM

Is Nextcure Inc’s -69.93% Fall This Year Is A Better Investing Opportunity? - Marketing Sentinel

08:02 AM

Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025

Apr 10, 2025

NextCure Updates Presentation on LNCB74 Clinical Trial - TipRanks

Apr 10, 2025

NextCure stock hits 52-week low at $0.3 amid sharp decline - Investing.com Australia

Apr 10, 2025

Apr 09, 2025

NextCure stock hits 52-week low at $0.3 amid sharp decline By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 04, 2025

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 04, 2025

Cancer Therapy Breakthrough? NextCure's Major Presentation at Needham Healthcare Conference - Stock Titan

Apr 04, 2025

Apr 03, 2025

CLASS ACTION UPDATE for PLAN, NXTC and BTU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire

Apr 03, 2025

Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India

Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia

Apr 01, 2025

Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India

Mar 25, 2025

Mar 20, 2025

ROSEN, A LEADING LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NXTC - Business Wire

Mar 20, 2025

Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025

Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India

Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa

Mar 18, 2025

NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 18, 2025

Mar 17, 2025

NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia

Mar 17, 2025

Mar 13, 2025

NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 13, 2025

Mar 10, 2025

NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times

Mar 07, 2025

Mar 06, 2025

NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq

Mar 06, 2025

Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan

Mar 06, 2025